An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma
Not yet recruitingCTIS2024-519504-27-00
Regeneron Pharmaceuticals Inc.Relapsed Refractory Multiple Myeloma
Target: 40Updated: 2026-02-10